Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

William Blair Downgrades DermTech to Market Perform

William Blair analyst Brian Weinstein downgrades DermTech (NASDAQ:DMTK) from Outperform to Market Perform.
byBenzinga Newsdesk
November 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

William Blair analyst Brian Weinstein downgrades DermTech (NASDAQ:DMTK) from Outperform to Market Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

SELLAS Life Sciences Reports Data In Completed Phase 1 Study Of Galinpepimut-S Combined With Opdivo In Advanced Malignant Pleural Mesothelioma; Primary Endpoint Of Safety And Efficacy Endpoint Met With Clinical Activity And Increased Survival Observed

By Happy Mohamed
June 28, 8:32 AM
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival Observed   70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy

SLS